Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 3/20 | 0.45 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 4/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15281442 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL15281431 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL10943934 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL2745005 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL7147865 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL12082938 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL7636758 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL7151360 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL17664724 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL6078563 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9370529-B2 | Tannin inhibitors of HIV | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160038520-A1 | TANNIN INHIBITORS OF HIV | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-02-11 | — | — | US | disclosed |
| US-9181291-B2 | Tannin inhibitors of HIV | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-20130252909-A1 | TANNIN INHIBITORS OF HIV | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8022192-B2 | Process for production of glucopyranosyloxypyrazole derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20110201793-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20090062518-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD, (JP) | 2009-03-05 | — | — | US | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201793-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | GCGR, UGGT1, GCKR | FGF1 533/4885SERPINC1 489/4885HPSE 1746/4885 |
| US-20130252909-A1 | TANNIN INHIBITORS OF HIV | SERPINB1, TSN, FURIN | FGF1 4025/4885SERPINC1 4/4885HPSE 355/4885 |
| US-20090062518-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | GCGR, UGGT1, GCKR | FGF1 533/4885SERPINC1 489/4885HPSE 1746/4885 |
| US-20160038520-A1 | TANNIN INHIBITORS OF HIV | SERPINB1, TSN, FURIN | FGF1 4025/4885SERPINC1 4/4885HPSE 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.